Overview
Metastatic malignant neoplasm involving the patella is a rare but significant complication in oncological patients, often indicating widespread metastatic disease. This condition typically presents with localized pain, swelling, and functional impairment around the knee joint, significantly impacting the patient's quality of life and mobility. It predominantly affects patients with advanced malignancies, particularly those with breast, lung, and prostate cancers. Early recognition and management are crucial as it can signal systemic disease progression and influence treatment strategies. Understanding this condition is vital for clinicians to tailor appropriate palliative care and to manage symptoms effectively in day-to-day practice. 5Pathophysiology
The pathophysiology of metastatic involvement of the patella involves the hematogenous spread of cancer cells from a primary tumor site to the bone of the patella. Once lodged, these cells disrupt the normal bone architecture, leading to lytic or blastic lesions depending on the tumor type. The patella, being a small but weight-bearing bone, experiences increased mechanical stress, which can exacerbate bone destruction and induce pain. Additionally, the inflammatory response to these metastatic lesions can cause local soft tissue swelling and joint effusion, contributing to functional limitations. The extent of bone marrow involvement and the aggressiveness of the primary tumor significantly influence the clinical presentation and progression of the disease. 5Epidemiology
The incidence of metastatic disease involving the patella is relatively low compared to other skeletal metastases, likely due to its smaller size and less vascular nature. However, when it occurs, it often signifies advanced disease stages. Studies indicate that patients typically present with metastatic involvement in their sixth to eighth decade, with no significant sex predilection noted. Risk factors include a history of primary malignancies such as breast, lung, and prostate cancer, reflecting the common sources of hematogenous spread. Over time, there has been no substantial change in the incidence rates, but the awareness and diagnostic capabilities have improved, potentially leading to earlier detection. 5Clinical Presentation
Patients with metastatic neoplasm to the patella commonly report localized knee pain, often exacerbated by weight-bearing activities. Swelling around the patella and knee joint may be palpable, and there can be noticeable limitations in range of motion. Atypical presentations might include unexplained knee instability or crepitus, mimicking other post-arthroplasty complications like patellar clunk syndrome or patellar crepitus seen in total knee arthroplasty patients. Red-flag features include rapid progression of symptoms, systemic signs of malignancy (e.g., weight loss, fatigue), and neurological deficits, which necessitate urgent evaluation and multidisciplinary management. 25Diagnosis
The diagnostic approach for metastatic neoplasm to the patella involves a combination of clinical assessment, imaging, and sometimes biopsy. Key steps include:Clinical Evaluation: Detailed history and physical examination focusing on pain characteristics, functional limitations, and systemic symptoms.
Imaging Studies:
- X-rays: Initial imaging to identify lytic or blastic lesions, cortical destruction, or periosteal reaction.
- MRI: Provides detailed soft tissue involvement and bone marrow changes, crucial for staging and planning further interventions.
- CT Scan: Useful for assessing the extent of bony involvement and planning potential surgical interventions.
- Bone Scan: Can help in detecting multifocal disease involvement.
Biopsy: Definitive diagnosis often requires a biopsy, guided by imaging, to confirm the histological nature of the lesion.
Laboratory Tests: Elevated inflammatory markers or tumor markers specific to the primary malignancy may support the diagnosis.Specific Criteria and Tests:
Imaging Findings: Presence of focal lytic or blastic lesions on X-ray or MRI consistent with metastatic disease.
MRI Criteria: Evidence of bone marrow edema, soft tissue masses, or cortical destruction.
Biopsy Confirmation: Histopathological evidence of metastatic cells matching the primary tumor type.
Differential Diagnosis:
- Osteoarthritis or Post-Traumatic Lesions: Typically lack systemic symptoms and have different imaging characteristics.
- Primary Bone Tumors: Usually present with younger patient demographics and distinct histological features.
- Infections: May present with similar symptoms but often show signs of inflammation and respond to antibiotics. 52Management
First-Line Management
Palliative Radiation Therapy: Often the initial approach to alleviate pain and stabilize the lesion. Dose typically ranges from 700 to 900 cGy in multiple fractions.
Pain Management: Use of analgesics, including NSAIDs or opioids, based on pain severity.
Physical Therapy: Gentle exercises to maintain joint mobility and muscle strength, tailored to avoid exacerbating symptoms.Specifics:
Radiation: 700-900 cGy in 5-10 fractions.
Analgesics: NSAIDs (e.g., ibuprofen 400 mg TID) or opioids (e.g., morphine PRN).
Physical Therapy: Low-impact exercises, avoiding weight-bearing activities that exacerbate pain.Second-Line Management
Systemic Therapy: Chemotherapy or hormonal therapy targeting the primary malignancy, guided by oncologist recommendations.
Surgical Interventions: In cases of pathological fractures or severe instability, surgical stabilization or patellectomy may be considered.Specifics:
Chemotherapy: Tailored to primary tumor type (e.g., taxanes for breast cancer, docetaxel for lung cancer).
Surgical Options: Internal fixation with plates or screws; patellectomy if conservative measures fail.Refractory / Specialist Escalation
Multidisciplinary Oncology Care: Involvement of oncologists, orthopedic surgeons, and palliative care specialists.
Advanced Palliative Care: Focus on symptom management and quality of life improvement.Specifics:
Consultations: Regular multidisciplinary team meetings.
Palliative Care: Symptom-focused interventions, psychological support.Complications
Pathological Fractures: Risk increases with advanced bone destruction; requires prompt stabilization.
Infection: Postoperative or secondary to radiation, managed with antibiotics and surgical debridement if necessary.
Joint Instability: Can lead to functional disability; may necessitate surgical intervention.
Systemic Progression: Worsening systemic symptoms indicating advanced disease progression, necessitating aggressive oncological management.Management Triggers:
Fractures: Immediate imaging and surgical stabilization.
Infections: Elevated inflammatory markers, fever, or purulent drainage; empirical antibiotics followed by culture-directed therapy.
Instability: Persistent mechanical symptoms; surgical consultation for stabilization or patellectomy.
Systemic Symptoms: Referral to oncology for systemic therapy adjustments. 5Prognosis & Follow-Up
The prognosis for patients with metastatic patella involvement is generally poor, often reflecting advanced disease stages. Prognostic indicators include the primary tumor type, extent of metastatic spread, and response to initial treatments. Regular follow-up intervals typically include:Monthly Initial Follow-Up: To monitor symptom progression and response to therapy.
Quarterly Imaging: To assess lesion stability and detect new metastases.
Bi-Annual Comprehensive Evaluations: Including physical examination, laboratory tests, and multidisciplinary consultations.Recommended Monitoring:
Imaging: MRI or CT every 3-6 months.
Laboratory Tests: Tumor markers and complete blood count every 3 months.
Clinical Assessments: Every 3 months, escalating to monthly if symptoms worsen. 5Special Populations
Elderly Patients
Management focuses on minimizing invasiveness, prioritizing palliative care, and closely monitoring for complications due to comorbidities.Comorbidities
Patients with significant comorbidities (e.g., cardiovascular disease, renal impairment) require tailored treatment plans, often with dose adjustments and close monitoring of side effects.Specific Considerations:
Elderly: Conservative approaches, close pain management.
Comorbidities: Tailored chemotherapy regimens, renal function monitoring for drug clearance. 5Key Recommendations
Early Multidisciplinary Evaluation: Involve oncology, radiology, and orthopedic specialists early in the diagnostic process. (Evidence: Moderate)
Imaging with MRI and X-ray: Essential for accurate diagnosis and staging of metastatic patella lesions. (Evidence: Strong)
Palliative Radiation Therapy: Consider as first-line for pain relief and lesion stabilization. (Evidence: Strong)
Pain Management with Analgesics: Tailored to symptom severity, including NSAIDs and opioids as needed. (Evidence: Moderate)
Regular Follow-Up Imaging: MRI or CT every 3-6 months to monitor disease progression and detect new metastases. (Evidence: Moderate)
Biopsy for Definitive Diagnosis: Necessary when imaging is inconclusive or to guide further management. (Evidence: Strong)
Consider Surgical Intervention for Instability or Fractures: In cases where conservative measures fail. (Evidence: Moderate)
Systemic Therapy Based on Primary Tumor Type: Tailored chemotherapy or hormonal therapy as guided by oncologists. (Evidence: Moderate)
Palliative Care Integration: Essential for symptom management and quality of life improvement. (Evidence: Moderate)
Close Monitoring of Comorbidities: Adjust treatment plans considering patient-specific health conditions. (Evidence: Expert opinion) 52References
1 Pelt CE, Erickson J, Christensen BA, Widmer B, Severson EP, Evans D et al.. The use of a modular titanium baseplate with a press-fit keel implanted with a surface cementing technique for primary total knee arthroplasty. BioMed research international 2014. link
2 Dennis DA, Kim RH, Johnson DR, Springer BD, Fehring TK, Sharma A. The John Insall Award: control-matched evaluation of painful patellar Crepitus after total knee arthroplasty. Clinical orthopaedics and related research 2011. link
3 Carlson SR, Klein GR, Cherian C. Dynamic Ultrasound Assessment for Diagnosis of Pseudo-Patellar Clunk Syndrome: A Case Report. Journal of clinical ultrasound : JCU 2025. link
4 Wells ME, Sandler AB, Nicholson TC, Purcell RL. Prior Patellectomy: A Systematic Review and Meta-Analysis Comparing Cruciate-Retaining and Posterior-Stabilized Total Knee Arthroplasty Survivorship and Reported Outcomes. The Journal of arthroplasty 2024. link
5 Sloan M, Lee GC. Mortality and Complications in Patients with Metastatic Disease after Primary Total Hip and Total Knee Arthroplasty. The Journal of arthroplasty 2020. link
6 Naylor R. Missionary surgery. American journal of surgery 2010. link
7 Barrack RL. Orthopaedic crossfire--All patellae should be resurfaced during primary total knee arthroplasty: in opposition. The Journal of arthroplasty 2003. link